Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 11/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26909947 | 0.79 | NLRP3 (0.47) | NLRP3MLLT1MAOB | |
| SCHEMBL24077256 | 0.71 | NLRP3 (0.62) | NLRP3 | |
| SCHEMBL24076410 | 0.70 | NLRP3 (0.53) | NLRP3 | |
| SCHEMBL24077348 | 0.70 | NLRP3 (0.57) | NLRP3MAPT | |
| SCHEMBL24076317 | 0.69 | NLRP3 (0.56) | NLRP3MAPT | |
| SCHEMBL24077350 | 0.69 | NLRP3 (0.55) | NLRP3MAPT | |
| SCHEMBL24077270 | 0.69 | NLRP3 (0.55) | NLRP3MAPT | |
| SCHEMBL24077405 | 0.69 | NLRP3 (0.55) | NLRP3MAPT | |
| SCHEMBL29492084 | 0.68 | POLB (0.48) | NLRP3 | |
| SCHEMBL24077172 | 0.68 | AKR1B1 (0.53) | NLRP3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217346-B1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-02 | — | — | EP | disclosed |
| US-20230391756-A1 | NEW COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-07 | — | — | US | disclosed |
| EP-4217346-A1 | NEW COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391756-A1 | NEW COMPOUND | NLRP3, NLRP1, IL1R1 | NLRP3 1/4885RET 4475/4885MLLT1 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.